Cytologic changes in cervical smears associated with prolonged use of depot-medroxyprogesterone acetate

Cancer

Volumn 84, Issue 6, 1998, Pages 328-334

  Valente, Philip T ^a,b   Schantz, H Daniel ^a   Trabal, Jose F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Atrophy; Cervical smears; Depot medroxyprogesterone acetate; Squamous and glandular atypia

Indexed keywords

MEDROXYPROGESTERONE ACETATE;

ADULT; AMENORRHEA; ARTICLE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOARCHITECTURE; CYTOPATHOLOGY; DIAGNOSTIC ERROR; FEMALE; HUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; SQUAMOUS CELL METAPLASIA; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROGESTERONE CONGENERS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0032567282     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981225)84:6<328::AID-CNCR3>3.0.CO;2-Z     Document Type: Article

References (15)

1. Papanicolaou GN. The diagnosis of early human pregnancy by the vaginal smear. Proc Soc Exp Biol Med 1925; 22:436-7.
2. Davidson HB, Hecht EL, Winston RL. The significance of abnormal postmenopausal smears. Am J Obstet Gynecol 1949;57:370-5.
3. Keebler CM, Wied GL. The estrogen test: an aid in the differential cytodiagnosis. Act Cytol 1974;18:482-93.
4. Kashimura M, Baba S, Nakamura S, Matsukuma K, Kamura T. Short-term estrogen test for cytodiagnosis in postmenopausal women. Diagn Cytopathol 1987;3:181-4.
5. Meisels A. The maturation value. Acta Cytol 1967;11:249.
6. Schwallie PC, Assenzo JR. Contraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973;24:331-9.
7. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 1996;41(Suppl):419-27.
8. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depo medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer 1991;49:186-90.
9. Bonte J, Decoster JM, Ide P. The vaginal cytologic evaluation as a practical link between hormone blood levels and tumor hormone dependency in exclusive medroxyprogesterone treatment of recurrent or metastatic endometrial adenocarcinoma. Acta Cytol 1977;21:218-24.
10. Koss LG. Diagnostic cytology and its histiopathologic bases. 4th edition. Philadelphia: J. B. Lippincott, 1992:300.
11. DeMay RM. The art and science of cytopathology. Chicago: ASCP Press, 1996:122.
12. Koss LG. Diagnostic cytology and its histopathologic bases. 4th edition. Philadelphia: J. B. Lippincott, 1992:682-3.
13. Valente PT, Schantz HD, Schultz M. Cytologic atypia associated with microglandular hyperplasia. Diagn Cytopathol 1994;10:326-31.
14. Fiorella RM, Brasfield K, Dubey S, McGuire S, Poole S, Kragel PJ. Cervical cytology associated with medroxyprogesterone acetate contraception [abstract]. Acta Cytol 1995;39:981.
15. Valente PT, Schantz HD, Fowler LJ, Trabal JF. Atypical squamous metaplasia versus high grade SIL: a high risk ASCUS [abstract]. Acta Cytol 1996;40:1040.